Bristol Myers Squibb's ZENBEXUS Shows Superior Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Phase 3 Study

Bristol Myers Squibb has announced positive topline results from its Phase 3 EXCALIBER-RRMM study, demonstrating that ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) significantly improved progression-free survival compared to the standard of care in patients with relapsed and refractory multiple myeloma. The data will be presented at the 68th Annual Meeting of the American Society of Hematology.